BioLineRx and Hemispherian Present Preclinical Data Demonstrating Synergy of GLIX1 with PARP Inhibitors in HR-Proficient Ovarian Cancer at ESMO 2026PRNewsWire · 1 day ago
BioLineRx and Hemispherian Announce Two GLIX1 Presentations at the 31st Society for Neuro-Oncology (SNO) Annual Meeting & Education DayPRNewsWire · Oct 8, 2026
BioLineRx and Hemispherian AS to Present Encouraging GLIX1 Preclinical Efficacy Data and its Phase 1/2a Trial Design at the 21st Meeting of the European Association of Neuro-Oncology (EANO 2026)PRNewsWire · Sep 10, 2026
BioLineRx Ltd. (BLRX) Q2 2026 Earnings Call TranscriptSeeking Alpha · Aug 31, 2026
BioLineRx Reports Second Quarter 2026 Financial Results and Provides Corporate UpdatePRNewsWire · Aug 31, 2026
BioLineRx Announces $3.75 Million Registered Direct Offering and Concurrent Private PlacementPRNewsWire · Aug 28, 2026BioLineRx Ltd., an Israeli biopharmaceutical firm established in 2003 and based in Hevel Modi'in, focuses its clinical-stage development efforts primarily on oncology. Their leading investigational product, Motixafortide, a peptide, has successfully concluded pivotal Phase 3 clinical trials for mobilizing stem cells in autologous transplants, and Phase 2a trials targeting pancreatic cancer. This compound is currently progressing through Phase 2 studies for metastatic pancreatic adenocarcinoma and Phase 1b trials for acute respiratory distress syndrome linked to COVID-19 and other viral infections.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 31, 2026 | -$0.15 | -$0.77 | Miss |
| May 27, 2026 | -$1.04 | -$0.58 | Beat |
| Mar 23, 2026 | -$0.50 | -$0.34 | Beat |
| Nov 24, 2025 | -$0.41 | -$0.22 | Beat |
| Aug 14, 2025 | -$0.35 | -$1.00 | Miss |
| May 27, 2025 | -$0.84 | $1.39 | Beat |